Gene therapy

Orthopaedic surgery
#Drug delivery #Funding #Gene therapy #Innovate UK #TherageniX #University of Nottingham

Innovate UK grant for powdered gene therapy

TherageniX and the University of Nottingham have been awarded a £995,000 ($1,252,585) grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery. Read More

#News

Cell and gene therapy
#CDMO #Cell and gene therapy #eBook #Gene therapy #Manufacturing

eBook: Analytical methods for viral vector development in gene therapy

The eleventh eBook of the Hamilton series ‘Analytical Methods for Viral Vector Development and Manufacturing in Gene Therapy’ is now available. Download the eBook to learn about: Gene therapy: history, viral vectors and the role of CDMOs Automation of analytical assays during viral vector development and manufacturing… Read More

#News

#CDMO #Cell and gene therapy #Gene therapy #Manufacturing

Analytical methods for viral vector development and manufacturing in gene therapy

In the eleventh eBook of the Hamilton series ‘Analytical Methods for Viral Vector Development and Manufacturing in Gene Therapy’, we learn about: Gene therapy: history, viral vectors and the role of CDMOs Automation of analytical assays during viral vector development and manufacturing The solutions that Hamilton offers to customers working… Read More

#Resources

Heart monitor
#AAV #Cardiovascular disease #Collaboration #Evox Therapeutics #Gene therapy #Icahn School of Medicine

Research partners advance AAV gene therapy for heart disease

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving… Read More

#News

Haemophilia
#CSL #Gene therapy #Haemophilia #National Institute for Health and Care Excellence (NICE)

UK health watchdog rejects gene therapy for haemophilia B

In a draft guidance consultation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend the use of Hemgenix (etranacogene dezaparvovec) on the NHS for treating haemophilia B (congenital factor IX deficiency). Although the gene therapy was granted a marketing authorisation by the UK Medicines… Read More

#News #Regulatory #Trending News

Human eye
#Cell and gene therapy #Gene therapy #Krystal Biotech #Ophthalmology

First-of-its-kind gene therapy restores vision in DEB patient

A dystrophic epidermolysis bullosa (DEB) patient at the Bascom Palmer Eye Institute, University of Miami, US, has regained his vision after being the first person to receive a formulation of gene therapy Vyjuvek suitable for the eyes. DEB is a rare genetic condition that makes the… Read More

#News #Trending News

#BioMarin Pharmaceuticals #Cell and gene therapy #FDA #Gene therapy #Haemophilia

One-time gene therapy for haemophilia A gets FDA green light

The US Food and Drug Administration (FDA) has approved the first gene therapy for adults with severe haemophilia A. BioMarin’s Roctavian (valoctocogene roxaparvovec-rvox) has been approved for the treatment of adults with severe haemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated… Read More

#News #Regulatory #Trending News

#Charles River #Drug discovery #Gene therapy #Human disease models #Immunotherapy #iPSC #Regenerative Medicine #Stem cells

Stem cells’ versatility in drug development  

This article is sponsored by Charles River. Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development.     Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug… Read More

#News

Gene therapy
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Webinar

Learn how to use adeno-associated virus (AAV) vectors in gene therapy

Join DDW for this exclusive free event, A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences.  AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Drug development #FDA #Gene therapy

New podcast episode: DDW Highlights 26 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Drug development #FDA #Gene therapy

This week in drug discovery (19-23 June)  

News round-up for 19-23 June by DDW Digital Content Editor Diana Spencer. Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been the announcement of the FDA’s approval of the first gene therapy for Duchenne muscular dystrophy, and a caution… Read More

#News

Approval stamp
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Gene therapy #Genetics / genomics #Muscular dystrophy #Sarepta Therapeutics

FDA approves first gene therapy for Duchenne muscular dystrophy

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. It is approved… Read More

#News #Regulatory #Trending News

AAV
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Webinar

A guide to using adeno-associated virus (AAV) vectors in gene therapy

Join DDW for this exclusive free event, A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences.  AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV… Read More

#News

AAV
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Plasmid DNA

A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy

AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. In this webinar, supported by Azenta Life Sciences, we’ll help you understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the… Read More

Webinar date:
Brought to you by Azenta Life Sciences
#Webinars

US Food and Drug Administration
#FDA #Gene therapy #Krystal Biotech #Rare disease

FDA approves first gene therapy for rare skin disorder

The US Food and Drug Administration has approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). It is approved for treating wounds in patients six months of age and older with mutation(s) in the collagen type VII alpha… Read More

#News #Regulatory #Trending News